Bivatuzumab BIWA 4: A New Treatment Candidate Bivatuzumab BIWA 4 represents a groundbreaking medicinal agent for managing multiple malignancies. This immunoglobulin selectively binds a critical molecule involved in tumor development and metastasis. Early clinical data indicate possibility for meaningful efficacy and a acceptable tolerability when